Wave Life Sciences Ltd

Stock Chart, Company Information, and Scan Results

$6.20(as of Mar 26, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Wave Life Sciences Ltd Company Information, Fundamentals, and Technical Indicators

Stock Price$6.20
Ticker SymbolWVE
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees317
CountyUSA
Market Cap$2,315.5M
EBIDTA-211.9M
10-Day Moving Average11.54
P/E Ratio-5.47
20-Day Moving Average12.56
Forward P/E Ratio0.00
50-Day Moving Average13.12
Earnings per Share-1.21
200-Day Moving Average10.19
Profit Margin-308.37%
RSI19.41
Shares Outstanding188.3M
ATR1.28
52-Week High21.73
Volume49,951,155
52-Week Low5.02
Most Recent Support Level11.13
Book Value526.2M
Most Recent Resistance Level12.67
P/B Ratio2.12
Upper Keltner15.43
P/S Ratio26.14
Lower Keltner9.69
Debt-to-Equity Ratio15.43
Next Earnings Date05/07/2026
Cash Surplus507.0M
Next Ex-Dividend DateUnknown

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.

Wave Life Sciences Ltd In Our Stock Scanner

As of Mar 27, 2026
example chart graphic
Scan Name: Undervalued StocksScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Momentum StocksScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: 52-Week LowScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Most Volatile StocksScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Undervalued Blue ChipsScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Unusual VolumeScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Oversold Stocks Scan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.